中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
18期
162-165,168
,共5页
夏海珊%陈少茹%钟月春%吕思敏%陈丽思%黄志荣%吴铁%邹丽宜
夏海珊%陳少茹%鐘月春%呂思敏%陳麗思%黃誌榮%吳鐵%鄒麗宜
하해산%진소여%종월춘%려사민%진려사%황지영%오철%추려의
肝纤维化%发病机制%药物治疗%甘草次酸
肝纖維化%髮病機製%藥物治療%甘草次痠
간섬유화%발병궤제%약물치료%감초차산
Liver fibrosis%Pathogenesis%Drug therapy%Glycyrrhetinic acid
为了解目前肝纤维化的发病机制及药物治疗现状,为临床及基础研究提供科学的方法及研究方向,本文综合国内外与肝纤维化的发病及治疗的相关文献40多篇,简要地阐述了医药界治疗肝纤维化的概况以及肝纤维化的发病机制,并总结了甘草次酸的主要药理作用,发现目前对肝纤维化的发病机制主要集中在肝星形细胞(HSCs)激活和转化为肌成纤维细胞与成纤维细胞、TGF-β信号转导、PDGF受体介导的信号转导通路、TNF-α介导的信号转导通路以及COX-2、ECM介导的肝纤维化、氧化应激介导的肝纤维化发生和发展。西医疗效还不十分理想,加上药物价格昂贵,不良反应大、阻碍了肝纤维化治疗的发展。而中医药治疗肝纤维化有其独特优势,不仅从单方面治疗肝纤维化,还兼顾脾肾等器官的保护,注重整体调理,辨证论治,中药治疗还具有价格优势,不良反应少等优点,值得研究。甘草次酸具有抗炎抗免疫作用、肾上腺皮质激素样作用、抗病毒、抗氧化、体外抑菌及保肝作用,并治疗肝纤维化提供了强而有力的±据,但甘草次酸治疗肝纤维化通过哪个途径进行仍然是现代医药研究热点和未知点。
為瞭解目前肝纖維化的髮病機製及藥物治療現狀,為臨床及基礎研究提供科學的方法及研究方嚮,本文綜閤國內外與肝纖維化的髮病及治療的相關文獻40多篇,簡要地闡述瞭醫藥界治療肝纖維化的概況以及肝纖維化的髮病機製,併總結瞭甘草次痠的主要藥理作用,髮現目前對肝纖維化的髮病機製主要集中在肝星形細胞(HSCs)激活和轉化為肌成纖維細胞與成纖維細胞、TGF-β信號轉導、PDGF受體介導的信號轉導通路、TNF-α介導的信號轉導通路以及COX-2、ECM介導的肝纖維化、氧化應激介導的肝纖維化髮生和髮展。西醫療效還不十分理想,加上藥物價格昂貴,不良反應大、阻礙瞭肝纖維化治療的髮展。而中醫藥治療肝纖維化有其獨特優勢,不僅從單方麵治療肝纖維化,還兼顧脾腎等器官的保護,註重整體調理,辨證論治,中藥治療還具有價格優勢,不良反應少等優點,值得研究。甘草次痠具有抗炎抗免疫作用、腎上腺皮質激素樣作用、抗病毒、抗氧化、體外抑菌及保肝作用,併治療肝纖維化提供瞭彊而有力的±據,但甘草次痠治療肝纖維化通過哪箇途徑進行仍然是現代醫藥研究熱點和未知點。
위료해목전간섬유화적발병궤제급약물치료현상,위림상급기출연구제공과학적방법급연구방향,본문종합국내외여간섬유화적발병급치료적상관문헌40다편,간요지천술료의약계치료간섬유화적개황이급간섬유화적발병궤제,병총결료감초차산적주요약리작용,발현목전대간섬유화적발병궤제주요집중재간성형세포(HSCs)격활화전화위기성섬유세포여성섬유세포、TGF-β신호전도、PDGF수체개도적신호전도통로、TNF-α개도적신호전도통로이급COX-2、ECM개도적간섬유화、양화응격개도적간섬유화발생화발전。서의료효환불십분이상,가상약물개격앙귀,불량반응대、조애료간섬유화치료적발전。이중의약치료간섬유화유기독특우세,불부종단방면치료간섬유화,환겸고비신등기관적보호,주중정체조리,변증론치,중약치료환구유개격우세,불량반응소등우점,치득연구。감초차산구유항염항면역작용、신상선피질격소양작용、항병독、항양화、체외억균급보간작용,병치료간섬유화제공료강이유력적±거,단감초차산치료간섬유화통과나개도경진행잉연시현대의약연구열점화미지점。
To study the pathogenesis of liver fibrosis and the present situation of disease treatment, provide the sci-entific methods and research direction for clinical and basic research, this summarize integrated both at home and abroad related to the pathogenesis and treatment of liver fibrosis with 40 references to expounds the pathogenesis and treatment of liver fibrosis. And sums up the main pharmacological action of glycyrrhetinic acid. In a nutshell, the pathogenesis of hepatic fibrosis currently focused on hepatic stellate cells (HSCs) activation and into muscle fiber cells and fibroblasts, TGF-βdecide signal transduction, PDGF signal transduction pathways, TNF-αmediated signal trans-duction pathways and COX-2, ECM mediated hepatic fibrosis and oxidative stress. On one hand, the current drug has not good effect on it, on the other hand, the expensive drug prices, side effects and adverse reactions, had hindered the development of liver fibrosis treatment. But Chinese medicine has its unique effect in treating liver fibrosis, not only from the unilateral treatment of liver fibrosis, also protect spleen kidney and other organs, and Chinese medicine treat-ment has price advantage, such as less adverse reaction, is worth studying. Glycyrrhetinic acid with good effect on an-ti-inflammatory immune function, adrenal cortical hormone kind function, antivirus, resistance to oxidation, in vitro antibacterial and protect liver function, and treatment of liver fibrosis, but the mechanism of glycyrrhetinic acid on the liver fibrosis is still unknown and worth to study.